

Special Issue

Vaccination and Treatments against Viral Hepatitis: Achievements, Challenges and Perspectives

Message from the Guest Editors

The vaccination era is a major global public health milestone that has led to the eradication of and reduction in infectious diseases. Vaccination has been important in reducing Hepatitis A and B cases in younger age groups in the context of viral hepatitis. In addition, vaccination against HBV, associated with immunoglobulin and prophylactic antiviral use, has led to a 90% reduction in cases of mother-to-child transmission and has also helped preventing Hepatitis D infection. As for the hepatitis C virus, despite the unavailability of a vaccine, the use of antiviral treatments has been promising and several studies for the development of an effective vaccine have been conducted. Vaccination against hepatitis E is only licensed in China, and more safety studies in children, the elderly, and other special populations are needed for future global deployment.

Guest Editors

Dr. Bárbara Vieira Do Lago

Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro 21040-900, Brazil

Dr. Vinicius M. Mello

Viral Hepatitis Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil

Deadline for manuscript submissions

closed (15 March 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/167718

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).